Mupirocin (Pseudomonic Acid A)

 Action Inhibits bacterial protein synthesis.

 Indications Topical treatment of impetigo caused by Staphylococcus aureus, Staphylococcus pyogenes, Streptococci, and Bacillus hemolyticus.

 Contraindications Standard considerations.

 Route/Dosage

ADULTS: Topical Apply tid for 3–5 days.

 Interactions None well documented.

 Lab Test Interferences None well documented.

 Adverse Reactions

DERM: Burning; stinging; pain; rash; itching; contact dermatitis.

 Precautions

Pregnancy: Category B. Lactation: Undetermined. Hypersensitivity: Chemical irritation may occur.

 Administration/Storage

• Apply topically only; avoid contact with eyes and mucous membranes. Treated area may be covered with gauze dressing.
• Wash hands before and after application.

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Assess for signs of superinfection (bacterial or fungal overgrowth of nonsusceptible organisms).
• Assess for therapeutic response: decrease in size and number of lesions.
• If a skin reaction develops, discontinue therapy, wash affected area and notify physician.

 Patient/Family Education

• Warn the patient to avoid contact of drug with eyes and mucous membranes.
• Instruct patient to wash hands before and after application.
• Tell patient to inform physician if no improvement is seen within 3–5 days or if condition worsens.
• Advise patient to keep fingernails well trimmed to prevent scratching.
• Review with patient and family appropriate hygiene measures to prevent spread of impetigo.
• Instruct patient to report these symptoms to physician: burning, stinging, pain, nausea, tenderness, swelling, rash, dry skin or increased exudate.